trending Market Intelligence /marketintelligence/en/news-insights/trending/r8r3WCrRuBIVXR5aX9tNQQ2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

J&J's single-tablet HIV regimen meets main goal of phase 3 Emerald study

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

J&J's single-tablet HIV regimen meets main goal of phase 3 Emerald study

Johnson & Johnson said its single-tablet regimen containing four HIV drugs met the main goal of a phase 3 study in infected adults whose viral levels were already controlled by medication.

The tablet — which includes darunavir 800 milligrams, cobicistat 150 milligrams, emtricitabine 200 milligrams and tenofovir alafenamide 10 milligrams worked as well as continuing treatment with a boosted protease inhibitor plus emtricitabine and tenofovir disoproxil fumarate in keeping HIV at bay, according to the Emerald trial by J&J's Janssen Pharmaceutica NV unit.

The study's main goal, as stipulated by the U.S. Food and Drug Administration, was the proportion of patients with virologic rebound, meaning that the viral level in the body has exceeded a certain threshold, through 48 weeks.

At the end of that period, cumulative virologic rebound was 2.5% for patients who switched to the single-tablet regimen, compared with 2.1% in those who continued their milligrams treatment.

Through 48 weeks, researchers did not observe any mutations that would have made the virus more resistant to treatment with the study drugs.

Virologic suppression was 94.9% for those taking the J&J tablet and 93.7% for the other patients at the end of 48 weeks. The single tablet failed to keep the virus below a certain level in 0.8% of patients, compared with 0.5% virologic failure for the other group. There were no discontinuations for virologic failure.

The single-tablet regimen also appeared to be as safe as the other combination.